Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with knee joint cartilage defect or injury of ICRS (International Cartilage Repair Society) Grade 4 confirmed by arthroscopy (At screening, patients diagnosed as such with an MRI may be included)~* Male or female patients at least 18 years of age~* Patients whose lesion (unilateral joint) is 2 ㎠ \~ 9㎠ in size~* Patients with articular swelling, tenderness and active range of motion of Grade 2 or below~* Patients with pain in affected joint of 60-mm or below on a 100-mm VAS (visual analogue scale)~* Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT \<1.5×control~* Patients with adequate renal function, Creatinine ≤ 2.0 ㎎/㎗, levels of proteinuria measured with Dipstick: trace or less~* Patients with adequate hepatic function, Bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L~* Patients who have received no surgery or radiation therapy in the affected joint within the past 6 six weeks, and have recovered from the side effects of such past treatments~* Female patients of childbearing potential must agree to practice adequate methods of birth control to prevent pregnancy during the study~* Patients whose physical examination results show no ligament instability of Grade II or above (Grade 0: none, Grade I: 0-5 mm, Grade II: 5-10 mm, Grade III: \>10 mm)~* Patients who voluntarily agreed to enroll in the study and signed an informed consent form~Exclusion Criteria:~* Patients with autoimmune disease or the medical history~* Patients with infections requiring parenteral administration of antibiotics~* Patients with myocardial infarction, ischemic heart failure, other serious heart conditions or uncontrolled hypertension, or any medical history of such diseases~* Patients with serious internal diseases~* Patients who are currently pregnant or nursing~* Patients with psychotic diseases, epilepsy, or any history of such diseases~* Patients with alcohol abuse~* Patients who smoke excessively~* Patients with chronic inflammatory articular diseases such as rheumatoid arthritis~* Patients who were enrolled in any other clinical trials within the past four weeks~* Patients who had been administered with immunosuppressants such as Cyclosporin A or azathioprine within the past six weeks~* Patients whose physical examination results show ligament instability of Grade II or above (Grade 0: none, Grade I: 0-5 mm, Grade II: 5-10 mm, Grade III: \>10 mm)~* Patients with a known history of hypersensitivity/allergy to gentamicin~* Patients who the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cartistem (Type: EXPERIMENTAL): A single dose of 500㎕/㎠ of cartilage defect
- Microfracture treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).